Siva Sundara Kumar Durairajan
Overview
Explore the profile of Siva Sundara Kumar Durairajan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
1086
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Patnaik S, Durairajan S, Singh A, Krishnamoorthi S, Iyaswamy A, Mandavi S, et al.
World J Gastroenterol
. 2024 Dec;
30(48):5212-5220.
PMID: 39735273
The gut microbiome plays a key role in the pathogenesis and disease activity of inflammatory bowel disease (IBD). While research has focused on the bacterial microbiome, recent studies have shifted...
2.
Durairajan S, Selvarasu K, Singh A, Patnaik S, Iyaswamy A, Jaiswal Y, et al.
Front Cell Neurosci
. 2024 Nov;
18:1432002.
PMID: 39507380
Alzheimer's disease (AD) is marked by the gradual and age-related deterioration of nerve cells in the central nervous system. The histopathological features observed in the brain affected by AD are...
3.
Singh A, Durairajan S, Iyaswamy A, Williams L
World J Gastroenterol
. 2024 Nov;
30(40):4404-4410.
PMID: 39494101
Hyperuricemia (HUA) is a condition associated with a high concentration of uric acid (UA) in the bloodstream and can cause gout and chronic kidney disease. The gut microbiota of patients...
4.
Durairajan S, Singh A, Iyaswamy A
World J Gastroenterol
. 2024 Oct;
30(35):3965-3971.
PMID: 39351059
In this editorial, we examine a paper by Koizumi , on the role of peroxisome proliferator-activated receptor (PPAR) agonists in alcoholic liver disease (ALD). The study determined whether elafibranor protected...
5.
Singh A, Selvarasu K, Durairajan S
Methods Mol Biol
. 2024 Mar;
2761:317-328.
PMID: 38427247
Tau protein in Alzheimer's disease (AD) and tauopathies becomes insoluble due to hyperphosphorylation, conformational alterations, and aggregation. To analyze insoluble tau and pathological tau species, this study employs a methodology...
6.
Selvarasu K, Singh A, Dakshinamoorthy A, Sreenivasmurthy S, Iyaswamy A, Radhakrishnan M, et al.
Biomedicines
. 2024 Jan;
12(1).
PMID: 38275365
Natively unfolded tau has a low propensity to form aggregates, but in tauopathies, such as Alzheimer's disease (AD), tau aggregates into paired helical filaments (PHFs) and neurofibrillary tangles (NFTs). Multiple...
7.
Durairajan S, Singh A, Saravanan U, Namachivayam M, Radhakrishnan M, Huang J, et al.
Viruses
. 2023 Jun;
15(6).
PMID: 37376531
The clinical manifestation of COVID-19, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in the respiratory system of humans is widely recognized. There is increasing evidence suggesting that...
8.
Selvarasu K, Singh A, Iyaswamy A, Sreenivasmurthy S, Krishnamoorthi S, Bera A, et al.
Front Mol Biosci
. 2022 Nov;
9:1050768.
PMID: 36387285
Many neurodegenerative diseases, such as Alzheimer's disease (AD) and frontotemporal dementia with Parkinsonism linked to chromosome 17, are characterized by tau pathology. Numerous motor proteins, many of which are involved...
9.
Sreenivasmurthy S, Iyaswamy A, Krishnamoorthi S, Reddi R, Kumar Kammala A, Vasudevan K, et al.
Front Mol Biosci
. 2022 Nov;
9:1030534.
PMID: 36387280
Emerging evidence from Alzheimer's disease (AD) patients suggests that reducing tau pathology can restore cognitive and memory loss. To reduce tau pathology, it is critical to find brain-permeable tau-degrading small...
10.
Iyaswamy A, Wang X, Krishnamoorthi S, Kaliamoorthy V, Sreenivasmurthy S, Durairajan S, et al.
Redox Biol
. 2022 Mar;
51:102280.
PMID: 35286997
Accumulation of amyloid-β (Aβ) oligomers and phosphorylated Tau aggregates are crucial pathological events or factors that cause progressive neuronal loss, and cognitive impairments in Alzheimer's disease (AD). Current medications for...